Caplin Point Laboratories (BOM:524742) EBIT : ₹5,652 Mil (TTM As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Caplin Point Laboratories EBIT?

Caplin Point Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ₹1,462 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹5,652 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Caplin Point Laboratories's annualized ROC % for the quarter that ended in Mar. 2024 was 25.90%. Caplin Point Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 45.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Caplin Point Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 5.67%.

Caplin Point Laboratories EBIT Historical Data

The historical data trend for Caplin Point Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caplin Point Laboratories EBIT Chart

Caplin Point Laboratories Annual Data

Trend

Jun15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

2,697.82

3,152.10

3,865.20

4,521.30

5,652.10

Caplin Point Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															1,242.80	1,272.70	1,461.80	1,455.80	1,461.80

Competitive Comparison of Caplin Point Laboratories's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caplin Point Laboratories's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Caplin Point Laboratories's EV-to-EBIT falls into.

Caplin Point Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,652 Mil.

Caplin Point Laboratories (BOM:524742) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Caplin Point Laboratories's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	5153.2 * ( 1 - 16.98% )	/	( (0	+	16517.1)	/ 1 )
=	4278.18664	/	16517.1
=	25.90 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	26973.8	-	2094.1	-	( 8362.6	-	max(0, 3305.6	-	18922.1	+	8362.6	))
=	16517.1

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Caplin Point Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	5847.2	/	( ( (0 + max(0, 0))	+	(5567.6 + max(7264.4, 0)) )	/	1 )
=	5847.2	/	( ( 0	+	12832 )	/	1 )
=	5847.2	/	12832
=	45.57 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(5427.2	+	3630.4	+	1501.9)	-	(2094.1	+	0	+	1201)
=	7264.4

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Caplin Point Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	5652.1	/	99652.529
	=	5.67 %

Caplin Point Laboratories EBIT Related Terms

Thank you for viewing the detailed overview of Caplin Point Laboratories's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Caplin Point Laboratories (BOM:524742) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Caplin Point Laboratories Ltd (BOM:524742) » Definitions » EBIT

Traded in Other Exchanges

CAPLIPOINT:India

Address

Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096

Website

https://www.caplinpoint.net

Caplin Point Laboratories Ltd is the India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, liquid orals, dry powder, soft gels, penems injections, suppositories. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops. The business of the company is organized into the following product segments, Antibiotics, Nsaids, Ophthalmics, Pain Management, and Antiulcers. Its products have a presence in the Latin American and African markets.

Caplin Point Laboratories (BOM:524742) Headlines

No Headlines